PT-141 (Bremelanotid)

PT-141 (Bremelanotide) is a synthetic melanocortin peptide that boosts sexual desire through the central nervous system. The US Food and Drug Administration (FDA) approved the active ingredient in June 2019 under the brand name Vyleesi as a subcutaneous injection for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Chemically, it is a cyclic heptapeptide made of seven amino acids and a direct derivative of Melanotan II. Its clinical effect is statistically significant, but in everyday life it often feels small.

What is PT-141 (Bremelanotide)?

PT-141 (Bremelanotide) is a synthetic peptide approved as a prescription drug for treating Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. It targets a persistent low sex drive that causes personal distress, as long as it is not explained by other factors like stress or medication. It is given only as a subcutaneous injection.

The drug was developed as a derivative of the synthetic peptide Melanotan II by Palatin Technologies and AMAG Pharmaceuticals (now sold by Covis Pharma under the brand name Vyleesi). Unlike blood-vessel-widening erectile dysfunction drugs like sildenafil, bremelanotide directly stimulates the brain's control centers in the central nervous system to trigger sexual arousal.

How is PT-141 used and dosed?

In the official FDA approval protocol, PT-141 is given as a subcutaneous injection under the skin at a standard dose of 1.75 mg about 45 minutes before sexual activity [1, 9]. It is used only as needed, with a strict limit of no more than one injection within 24 hours.

In early phase II studies, PT-141 was also tested as an intranasal spray in doses of 4 to 20 mg [6]. This form, however, was never approved. On the unregulated gray market, PT-141 is usually sold as a freeze-dried powder in vials that users have to dissolve themselves with BAC water and inject - a practice with no pharmaceutical quality checks or official safety oversight.

The plasma half-life of PT-141 is about 2.7 hours, so the drug concentration in the blood drops to a quarter of its peak value after 5 to 6 hours [9]. The math for reconstituting the powder is explained in the next section.

How does reconstitution of PT-141 from vial to injection work?

The FDA-approved finished drug Vyleesi comes ready to use, with 1.75 mg of Bremelanotide in 0.3 mL of injection solution per autoinjector. Gray-market products, on the other hand, are typically sold as freeze-dried powder in 10 mg vials. Manually mixing and dosing these vials is based on community protocols and carries significant microbial risks without a sterile lab environment.

If you reconstitute a 10 mg vial with 2 mL of BAC water (bacteriostatic water with benzyl alcohol as a preservative), you get a concentration of 5 mg of PT-141 per milliliter. For the standard clinical dose of 1.75 mg, you need to draw up 0.35 mL (which equals 35 units on a U-100 insulin syringe); for a lower dose of about 1.25 mg, it is 0.25 mL (25 units).

These dosing steps describe only the volume ratios, with no guarantee of purity or actual drug content. For a practical overview, check the guide on instructions for mixing and storing, and the injection calculator helps with individual concentration calculations. Reconstituted solutions must be kept refrigerated at all times to prevent the peptide from breaking down quickly.

How does PT-141 work in the brain?

PT-141 works as an agonist at the melanocortin receptors MC3R and MC4R in the hypothalamus, a central control center in the brain for automatic and behavioral processes. By binding to these receptors, the peptide mimics the body's own hormone alpha-MSH, which, besides controlling pigmentation, also regulates neural arousal patterns and feelings of pleasure.

By activating the MC3/MC4 signaling pathways, Bremelanotide influences basic neural circuits for appetite, sleep, and sexual behavior. This receptor stimulation triggers arousal-promoting signals in the central nervous system. The binding profile to different melanocortin subtypes is described in the scientific literature as both selective and non-selective.

How effective is PT-141 in clinical studies and in practice?

PT-141 causes a statistically measurable increase in sexual desire in premenopausal women with HSDD, but in everyday treatment, patients often notice only a small difference. There are a few studies on its effect in men with erectile dysfunction, but the evidence is not enough for any medical approval or recommendation.

While the phase III approval studies showed significant improvements on validated HSDD scores, methodological follow-up analyses temper the practical relevance in daily life. An early clinical study in men with erectile dysfunction reported a response rate of 33.5% with PT-141 compared to 8.5% with placebo [6], but this was not enough for a regulatory approval.

What did the RECONNECT study program on Bremelanotide examine?

The RECONNECT program included two randomized, placebo-controlled phase III studies with over 1,200 premenopausal women at about 80 study centers in the US and Canada. Over a 24-week treatment period, the program provided the key efficacy and safety data for the US approval of 1.75 mg of Bremelanotide.

To assess long-term tolerability, a safety study by Simon et al. (2019) analyzed 684 patients over 52 weeks. Earlier dose-finding studies tested doses of 0.75 mg, 1.25 mg, and 1.75 mg subcutaneously compared to placebo, to find the most effective dose range with an acceptable side effect profile.

Which dose of PT-141 is supported by studies?

The single dose of PT-141 tested in clinical studies and approved by the FDA is 1.75 mg subcutaneously, taken as needed at least 45 minutes before sexual activity. Because of the risk of temporary blood pressure spikes, you must not have more than one injection within 24 hours; the half-life is 2.7 hours.

In phase II dose-finding studies, doses of 0.75 mg and 1.25 mg were tested, but only 1.75 mg produced a statistically significant increase in satisfying sexual events. The strict daily maximum of one dose per 24 hours is meant to protect against sudden cardiovascular strain.

How do you handle and store PT-141 and Vyleesi?

The finished drug Vyleesi is injected with a pre-filled subcutaneous autoinjector into the fat tissue of the abdomen or thigh, which reduces handling and dosing errors. In contrast, freeze-dried peptide powder from research contexts requires manual mixing under sterile conditions and continuous refrigeration.

Original Vyleesi autoinjectors can be stored at controlled room temperature or in the refrigerator, according to the manufacturer. Reconstituted PT-141 powder in vials, however, must be kept in the refrigerator, protected from light, to prevent the peptide chain from breaking down quickly due to enzymes and heat.

What side effects and risks does PT-141 have?

The most common side effects of PT-141 include temporary cardiovascular reactions with a sudden rise in blood pressure and a slower heart rate, as well as nausea and skin darkening. This darkening usually shows up as a dark discoloration of the gums, facial skin, or nipples, and it usually fades after you stop taking the drug.

Because of its effects on blood pressure, Bremelanotide is contraindicated in people with uncontrolled high blood pressure. Taking it orally as a capsule or tablet does not work, because the peptide structure is broken down by enzymes in the digestive tract.

• Common mistake 1: Panicking about skin changes. A sudden darkening of the gums or nipples is a known side effect of melanocortin activation and is usually reversible.
• Common mistake 2: Ignoring blood pressure. Since PT-141 can raise blood pressure and lower heart rate, you should avoid it if you have heart or blood vessel problems.
• Common mistake 3: Expecting a mechanical erection. Unlike PDE5 inhibitors, PT-141 works centrally on sexual desire in the brain and does not produce an automatic physical erection.

What is the legal status of PT-141 in Germany and the EU?

Bremelanotide has been approved only in the US by the FDA as a prescription drug (Vyleesi) since June 2019. In the European Union and the DACH region, there is no market approval. Buying it from online peptide shops happens in unregulated gray areas without official quality or purity standards.

Neither the European Medicines Agency (EMA) nor the Swiss agency Swissmedic has approved PT-141 as a drug. If you order the substance in Germany, Austria, or Switzerland as a research chemical, you are buying an uncontrolled gray-market product with a higher risk of impurities. For more details on how to reduce risks, see the information page on protection when ordering.